Supernus Pharmaceuticals

SUPN

Market cap $2.8B

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric (6 to 17 years) ADHD in April 2021, and subsequent approval for adults in April 2022, Qelbree has served as a valuable option for the nearly 16 million adults and 7 million children and teens living with ADHD in the U.S.,1,2 showcasing Supernus' 25+ year legacy in ADHD research.

Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.

ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.